Identification of acrolein-conjugated protein in plasma of patients with brain infarction.
It is known that the level of protein-conjugated acrolein in plasma is a good marker of chronic renal failure and brain infarction. Thus, studies were carried out to determine which kinds of plasma proteins are conjugated with acrolein. It was found that acrolein was mainly conjugated with albumin. Tandem mass spectrometry analysis demonstrated that Lys-557 and Lys-560, located at the surface of domain III of albumin, were the major sites conjugated with acrolein. This is the first report to identify the amino acid residues in a protein modified by acrolein in vivo. It was found that conjugation of acrolein with albumin contributed to a decrease in the toxicity of acrolein.
Yoshida
Madoka
M
Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan.
Higashi
Kyohei
K
Jin
Lihua
L
Machi
Yoshiki
Y
Suzuki
Takehiro
T
Masuda
Akiko
A
Dohmae
Naoshi
N
Suganami
Akiko
A
Tamura
Yutaka
Y
Nishimura
Kazuhiro
K
Toida
Toshihiko
T
Tomitori
Hideyuki
H
Kashiwagi
Keiko
K
Igarashi
Kazuei
K
D000171:Acrolein / Q000737:chemistry / Q000378:metabolism*; D000595:Amino Acid Sequence; D015415:Biomarkers / Q000737:chemistry / Q000378:metabolism; D020520:Brain Infarction / Q000097:blood*; D006801:Humans; D008239:Lysine / Q000737:chemistry / Q000378:metabolism; D008969:Molecular Sequence Data; D018384:Oxidative Stress; D017434:Protein Structure, Tertiary; D012709:Serum Albumin / Q000737:chemistry / Q000378:metabolism*; D053719:Tandem Mass Spectrometry
D015415:Biomarkers; D012709:Serum Albumin; D000171:Acrolein; D008239:Lysine